Implantica
41.2 SEK +0.49%1 investor is following this company
Implantica is active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes implantable medical instruments, which are further used for the treatment of diseases that affect the esophagus. In addition to the main business, service and related ancillary services are also offered, especially focused on eHealth. Implantica operates worldwide, with the largest presence in North America and Europe.
Revenue
15.7M
EBIT %
-1,548.94 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
IMP A SDB
Daily low / high price
41.15 / 41.2
SEK
Market cap
48.74B SEK
Turnover
50.96K SEK
Volume
1.2K
Latest videos
Financial calendar
Interim report
15.11.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Peter Forsell | 47.4 % | 47.4 % |
| Handelsbanken Fonder | 8.6 % | 8.6 % |
| EFG Bank | 7.1 % | 7.1 % |
| UBP | 2.8 % | 2.8 % |
| Avanza Pension | 2.6 % | 2.6 % |
| SEB Life | 2.3 % | 2.3 % |
| UBS | 2.1 % | 2.1 % |
| TIN Fonder | 1.7 % | 1.7 % |
| SIX SIS AG | 1.5 % | 1.5 % |
| Stephan Siegenthaler | 1.3 % | 1.3 % |
ShowingAll content types
Implantica announces highly successful 2024 American Foregut Society meeting where RefluxStop® received remarkable pre-launch market feedback
Implantica welcomes 23 top anti-reflux surgeons from 17 leading centers in the first User meeting in Spain, 1.5 years post country launch
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Implantica shares a landmark review article on standard of care Nissen Fundoplication anti-reflux surgery - in light of the recently announced excellent RefluxStop[TM] 5-year results
Implantica announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop™
Implantica conducts first national RefluxStop™ User meeting with 21 participating surgeons, 1.5 years after launch in Italy
Implantica announces excellent data from an independent study of 158 RefluxStop™ patients from two centers in Germany - presented at the AUGIS meeting in UK
Implantica mourns the death of board member Prof. Dr. Klaus Neftel
